Friday, AbbVie Inc (NYSE:ABBV) reported fourth-quarter adjusted EPS of $2.79, down 22.5% Y/Y, beating the consensus of $2.77. Fourth-quarter net revenues reached $14.301 billion, down 5.4% Y/Y, beating the consensus of $14.02 billion. The immunology portfolio generated $6.95 billion in sales, down 12.3%. Humira revenues were $3.30 billion (down 40.8%), Skyrizi sales reached $2.39 billion (up 51.9%), and Rinvoq revenues were $1.26 billion (up 62.9%). Related: Aesthetics Market Resilience: AbbVie
The FTSE 100 closed Tuesday up 0.07%, outperforming European peers. The index is holding up well, largely due to the continued weakness in the pound and a belief that a weaker currency and higher.
The FTSE 100 closed down 0.7% despite the short-lived boost stocks enjoyed after the Bank of England voted to keep its key interest rate unchanged at 5.25%, ending a run of 14 consecutive rises..
The FTSE 100 Closed Down Despite the Bank of England Leaving Rates Unchanged morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
Netflix subscriber numbers jump on password-sharing crackdown, United Airlines flies high on international travel boom, and other news to start your day.